Whereas FXR activation generally has protective effects [73], alterations in the bile acid pool, particularly the elevation of the levels of certain secondary bile acids, have been associated with MASLD progression [74]. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.